BMEA
Biomea Fusion, Inc.1.3700
+0.0300+2.24%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
96.86MP/E (TTM)
-Basic EPS (TTM)
-2.25Dividend Yield
0%Recent Filings
8-K
Q3 loss halves; trials advance
Biomea Fusion reported Q3 2025 net loss of $16.4M, down from $32.8M YoY, after slashing R&D expenses 47% to $14.4M and workforce to 40 employees. Icovamenib showed durable 1.5% HbA1c reduction at 52 weeks in insulin-deficient T2D patients; BMF-650 dosed first Phase I patient. Raised ~$68M via offerings, extending runway to Q1 2027. New trials launch Q4 2025.
10-Q
Q3 FY2025 results
Biomea Fusion narrowed Q3 operating losses to $20.8M from $34.0M y/y, driven by 47% cuts in R&D spend to $14.4M and G&A to $4.2M, reflecting headcount reductions and ceased lab use; a $2.2M one-time asset impairment hit while $4.4M interest/other income (from warrant fair-value gains) trimmed net loss to $16.4M ($0.27/share) versus $32.8M ($0.91/share) last year. YTD losses improved to $66.4M from $109.1M, with cash burn slowing to $56.4M operating use; equity raises added $44.8M, leaving $46.6M cash (plus $0.4M restricted). Cash runway extends into Q1 2027. Clinical costs dropped sharply across COVALENT trials. Going concern warning flags need for more capital. Pipeline rests on unproven icovamenib and early BMF-650; trial delays loom large.
8-K
Icovamenib shows lasting HbA1c cuts
Biomea Fusion reported 52-week data from its Phase II COVALENT-111 study on October 6, 2025, showing icovamenib delivered durable HbA1c reductions in type 2 diabetes patients. In severe insulin-deficient cases, the drug cut HbA1c by 1.2% (p=0.01) through week 52 after 12 weeks of dosing, with Arm B achieving 1.5% (p=0.01). It also aided those on GLP-1 therapies, dropping HbA1c 1.3% (p=0.05), all while maintaining a clean safety profile—no serious adverse events. Company plans Phase IIb and II trials in Q4 2025. Interim results may not predict final outcomes.
10-Q
Q2 FY2025 results
Biomea Fusion narrowed its Q2 net loss to $20.7M from $37.3M a year earlier, as research and development expenses dropped 48% year-over-year to $16.6M amid a strategic pivot to metabolic disorders, slashing clinical costs in oncology trials while advancing Phase II studies of icovamenib in type 1 and type 2 diabetes. Operating expenses fell sharply quarter-over-quarter too, reflecting headcount reductions and efficiency gains. Cash burn eased to $44.9M for the half-year, bolstered by $42.8M from a June equity offering, leaving $56.6M in cash and equivalents at quarter-end—enough to fund operations into late 2026, though additional capital will be needed. No free cash flow or non-GAAP metrics disclosed in the 10-Q. Yet clinical delays remain a persistent hurdle.
8-K
Q2 loss narrows amid cuts
Biomea Fusion reported Q2 2025 net loss of $20.7 million, down from $37.3 million last year, thanks to slashed R&D expenses from $31.8 million to $16.6 million after workforce cuts. Cash stands at $56.6 million, bolstered by $42.8 million from a public offering, funding operations into H2 2026. Icovamenib showed durable HbA1c reductions in T2D patients and superior combo benefits with semaglutide in rats, while BMF-650 drove 15% weight loss in primates. Pivoting from oncology sharpens focus on metabolic programs.
BDRX
Biodexa Pharmaceuticals plc
6.50+1.72
BIOA
BioAge Labs, Inc.
12.51+0.05
IBIO
iBio, Inc.
2.06+0.23
IBO
Impact BioMedical, Inc.
0.44-0.02
IMA
ImageneBio, Inc.
6.25+0.08
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MTSR
Metsera, Inc.
70.50-0.25
MTVA
MetaVia Inc.
8.14-0.17
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SANA
Sana Biotechnology, Inc.
5.00-0.08